MOBI (MOBI) Stock Analysis
Verdict: AVOID
Strong insider buying and 82.8% gross margins are undercut by an unsustainable ~9-month cash runway and severe earnings misses.
Investment score: 35/100
Is MOBI Stock Worth Reviewing? AI Model Thesis
The model recommends avoiding MOBI despite strong insider accumulation due to imminent capital dilution risks, severe earnings misses, and negative equity.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| SI | -10.04 | 2.86 | 5.93 | -10.48 | — | -0.58 |
| OBIO | -6.16 | 13.23 | 11.42 | -7.28 | — | -1.85 |
| CV | -10.38 | 24.81 | 23.52 | -10.75 | — | -2.15 |
| TMCI | -4.94 | 4.41 | 1.45 | -7.91 | — | -0.29 |
Should You Buy or Sell MOBI Stock? Model Reasoning
The AI model views MOBI as an AVOID due to high capital structure risk. While 82.8% gross margins and recurring insider purchases between $10.30 and $12.53 signal product potential, annual operating cash flow of -$45.69M against $33.59M in cash gives MOBI less than 9 months of runway. Dilution risk is extreme, confirmed by net equity of -$150.77M and severe EPS misses (-66.8% in Q2 2026).
MOBI Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Annual operating cash burn remains above $40M, requiring dilutive equity financing within 6–12 months.","Revenue grows from $32.04M in 2025 to $80.0M by FY 2027 as projected by analyst consensus.","Gross margins remain structurally high near 80%–82%, but operating expense reduction remains slow."]
MOBI Risk & Opportunity Analysis
Key Investment Risks
- Severe Liquidity and Dilution Risk — Annual operating cash burn of -$45.69M against $33.59M in cash reserves leaves ~8.8 months of operational runway, forcing secondary stock offerings or dilutive debt before Q3 2027.
- Persistent Execution and Earnings Shortfalls — Q1 2026 EPS missed estimates by -3806.9% and Q2 2026 missed by -66.8%, signaling major operational forecasting errors and commercial friction in hospital uptake.
- Negative Equity and Debt Liabilities — Total equity stands at -$150.77M with accumulated deficits of -$157.79M, creating potential solvency issues if credit conditions tighten or dilution occurs at depressed stock prices.
- Valuation Compression Relative to Peers — P/S ratio of 12.04x trades significantly higher than peers like TMCI (1.45x) and SI (5.93x), leaving the valuation vulnerable to further multiples contraction if 2027 revenue misses $80M.
Growth Opportunities & Upside Drivers
- High Unit-Economics Gross Margins — TTM gross margin of 82.8% exceeds peers like SI (77.3%) and CV (50.9%), providing high operational leverage once commercial sales scale toward $80M in projected 2027 consensus revenue.
- Sustained Cluster of Insider Buying — Seven insider buy transactions with zero sells, led by Director Casey Tansey buying at $11.50–$12.53 in August 2026, demonstrate strong internal confidence in Vivistim platform adoption.
- Broad Street Target Premium — Consensus analyst price target of $25.00 represents >160% upside from $9.28, supported by 9 Buy/Strong Buy recommendations against 1 Hold.
- Platform Pipeline Expansion — Expanding paired VNS indications beyond stroke rehabilitation into chronic conditions like tinnitus enlarges total addressable market over the 2027–2029 projection window.
MOBI Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About MOBI (MOBI)
Is MOBI stock a good investment?
The cached TradeMates AI model rates MOBI as AVOID with an investment score of 35/100. The model recommends avoiding MOBI despite strong insider accumulation due to imminent capital dilution risks, severe earnings misses, and negative equity. This is algorithmic model output, not personal investment advice.
Does MOBI pay a dividend?
The cached stock data on this page does not show a positive dividend yield for MOBI. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does MOBI stock do?
Mobia Medical develops and commercializes implantable neurostimulation medical devices, primarily the FDA-approved Vivistim System, which pairs vagus nerve stimulation (VNS) with physical therapy for post-stroke upper limb motor rehabilitation.
What is MOBI stock's price target?
This cached page does not contain a precise model fair value for MOBI.
Is MOBI stock a buy?
The TradeMates model verdict for MOBI is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.
Is MOBI a good dividend stock?
MOBI is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.